pI: 6.7982 |
Length (AA): 383 |
MW (Da): 43724 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 6
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There is 1 model calculated for this protein. More info on
this model, including the
model itself is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
146 | 187 | 5b8i (C) | 76 | 117 | 33.00 | 0.57 | 0.23 | 0.290761 | 1.65 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | ME49 Oocyst. | Fritz HM |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | VEG Tachyzoite, ME49 Tachyzoite, ME49 merozoite. | Gregory Hehl AB |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | ME49 Bradyzoite. | Sibley/Greg |
Gregory | ToxoDB |
Hehl AB | Asexual expansion of Toxoplasma gondii merozoites is distinct from tachyzoites and entails expression of non-overlapping gene families to attach, invade, and replicate within feline enterocytes. |
Sibley/Greg | ToxoDB |
Fritz HM | Transcriptomic analysis of toxoplasma development reveals many novel functions and structures specific to sporozoites and oocysts. |
Ortholog group members (OG5_126838)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G26200 | TRAM, LAG1 and CLN8 (TLC) lipid-sensing domain containing protein |
Arabidopsis thaliana | AT3G19260 | LAG1 longevity assurance-like 2 |
Arabidopsis thaliana | AT3G25540 | LAG1 longevity assurance-1 |
Arabidopsis thaliana | AT1G13580 | ceramide synthase LAG1 |
Babesia bovis | BBOV_III005530 | hypothetical protein |
Brugia malayi | Bm1_06625 | homolog of yeast longevity gene protein 2 |
Candida albicans | CaO19.7354 | Longevity-assurance gene 1 cognate (LAG1 cognate) |
Caenorhabditis elegans | CELE_K02G10.6 | Protein HYL-2 |
Caenorhabditis elegans | CELE_C09G4.1 | Protein HYL-1 |
Dictyostelium discoideum | DDB_G0282607 | ceramide synthase |
Drosophila melanogaster | Dmel_CG3576 | CG3576 gene product from transcript CG3576-RA |
Echinococcus granulosus | EgrG_001184400 | lag1 longevity assurance 5 |
Entamoeba histolytica | EHI_139080 | longevity-assurance family protein |
Entamoeba histolytica | EHI_151290 | longevity-assurance family protein |
Echinococcus multilocularis | EmuJ_001184400 | lag1 longevity assurance 5 |
Giardia lamblia | GL50803_5939 | Hypothetical protein |
Homo sapiens | ENSG00000172292 | ceramide synthase 6 |
Homo sapiens | ENSG00000090661 | ceramide synthase 4 |
Homo sapiens | ENSG00000139624 | ceramide synthase 5 |
Homo sapiens | ENSG00000143418 | ceramide synthase 2 |
Leishmania braziliensis | LbrM.31.2010 | dihydroceramide synthase, putative |
Leishmania donovani | LdBPK_311800.1 | Sphingosine N-acyltransferase, putative |
Leishmania infantum | LinJ.31.1800 | dihydroceramide synthase, putative |
Leishmania major | LmjF.31.1780 | dihydroceramide synthase, putative |
Leishmania mexicana | LmxM.30.1780 | hypothetical protein, conserved |
Loa Loa (eye worm) | LOAG_08632 | hypothetical protein |
Mus musculus | ENSMUSG00000027035 | ceramide synthase 6 |
Mus musculus | ENSMUSG00000008206 | ceramide synthase 4 |
Mus musculus | ENSMUSG00000023021 | ceramide synthase 5 |
Mus musculus | ENSMUSG00000015714 | ceramide synthase 2 |
Neospora caninum | NCLIV_058920 | hypothetical protein |
Oryza sativa | 4332339 | Os03g0264000 |
Oryza sativa | 4330600 | Os02g0728300 |
Oryza sativa | 4329785 | Os02g0581300 |
Oryza sativa | 9268169 | Os09g0372700 |
Plasmodium berghei | PBANKA_1038300 | translocation associated membrane protein, putative |
Plasmodium falciparum | PF3D7_1403700 | translocation associated membrane protein, putative |
Plasmodium knowlesi | PKNH_1354400 | translocation associated membrane protein, putative |
Plasmodium vivax | PVX_086250 | hypothetical protein, conserved |
Plasmodium yoelii | PY00812 | tumor metastasis-suppressor |
Schistosoma japonicum | Sjp_0302590 | LAG1 longevity assurance homolog 5, putative |
Schistosoma mansoni | Smp_042440 | dihydroceramide synthase |
Schmidtea mediterranea | mk4.002284.03 | |
Schmidtea mediterranea | mk4.009230.00 | |
Schmidtea mediterranea | mk4.009105.00 | |
Trypanosoma brucei gambiense | Tbg972.8.7980 | hypothetical protein, conserved |
Trypanosoma brucei gambiense | Tbg972.4.4900 | hypothetical protein, conserved |
Trypanosoma brucei | Tb927.8.7730 | Sphingosine N-acyltransferase, putative |
Trypanosoma brucei | Tb927.4.4740 | Sphingosine N-acyltransferase, putative |
Trypanosoma congolense | TcIL3000_0_57130 | Sphingosine N-acyltransferase, putative |
Trypanosoma congolense | TcIL3000_0_38500 | Sphingosine N-acyltransferase, putative |
Trypanosoma congolense | TcIL3000_0_52910 | Sphingosine N-acyltransferase, putative |
Trypanosoma congolense | TcIL3000_0_02670 | Sphingosine N-acyltransferase, putative |
Trypanosoma cruzi | TcCLB.510087.30 | Sphingosine N-acyltransferase, putative |
Trypanosoma cruzi | TcCLB.507395.10 | Sphingosine N-acyltransferase, putative |
Toxoplasma gondii | TGME49_316450 | longevity-assurance protein (LAG1) domain-containing protein |
Theileria parva | TP02_0395 | hypothetical protein, conserved |
Trichomonas vaginalis | TVAG_254300 | longevity assurance factor, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.4740 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.4740 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.4740 | Trypanosoma brucei | significant loss of fitness in procyclic forms | alsford |
Tb927.4.4740 | Trypanosoma brucei | significant loss of fitness in differentiation of procyclic to bloodstream forms | alsford |
Tb927.8.7730 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.8.7730 | Trypanosoma brucei | significant loss of fitness in bloodstream forms (6 days) | alsford |
Tb927.8.7730 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.8.7730 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
PBANKA_1038300 | Plasmodium berghei | Dispensable | plasmo |
TGME49_316450 this record | Toxoplasma gondii | Essentiality uncertain | sidik |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.